Methodology to Assess Clinical Liver Safety Data

被引:26
作者
Merz, Michael [1 ]
Lee, Kwan R. [2 ]
Kullak-Ublick, Gerd A. [1 ,3 ]
Brueckner, Andreas [4 ]
Watkins, Paul B. [5 ,6 ,7 ,8 ]
机构
[1] Novartis Inst BioMed Res, Discovery & Invest Safety, CH-4057 Basel, Switzerland
[2] GlaxoSmithKline, Med Analyt, Collegeville, PA USA
[3] Univ Zurich Hosp, Dept Clin Pharmacol & Toxicol, CH-8091 Zurich, Switzerland
[4] Novartis Pharma AG, Basel, Switzerland
[5] Hamner Univ North Carolina, Inst Drug Safety Sci, Res Triangle Pk, NC USA
[6] Univ N Carolina, Sch Med, Chapel Hill, NC USA
[7] Univ N Carolina, Sch Pharm, Chapel Hill, NC USA
[8] Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC USA
关键词
BIOMARKERS;
D O I
10.1007/s40264-014-0184-5
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Analysis of liver safety data has to be multivariate by nature and needs to take into account time dependency of observations. Current standard tools for liver safety assessment such as summary tables, individual data listings, and narratives address these requirements to a limited extent only. Using graphics in the context of a systematic workflow including predefined graph templates is a valuable addition to standard instruments, helping to ensure completeness of evaluation, and supporting both hypothesis generation and testing. Employing graphical workflows interactively allows analysis in a team-based setting and facilitates identificatio\n of the most suitable graphics for publishing and regulatory reporting. Another important tool is statistical outlier detection, accounting for the fact that for assessment of Drug-Induced Liver Injury, identification and thorough evaluation of extreme values has much more relevance than measures of central tendency in the data. Taken together, systematical graphical data exploration and statistical outlier detection may have the potential to significantly improve assessment and interpretation of clinical liver safety data. A workshop was convened to discuss best practices for the assessment of drug-induced liver injury (DILI) in clinical trials.
引用
收藏
页码:S33 / S45
页数:13
相关论文
共 23 条
[11]   The current state of serum biomarkers of hepatotoxicity [J].
Ozer, Josef ;
Ratner, Marcia ;
Shaw, Martin ;
Bailey, Wendy ;
Schomaker, Shelli .
TOXICOLOGY, 2008, 245 (03) :194-205
[12]  
Parks D, 2013, PHARMACOEPIDEMIOL DR
[13]   Additive effects of moderate drinking and obesity on serum γ-glutamyl transferase activity [J].
Puukka, Katri ;
Hietala, Johanna ;
Koivisto, Heidi ;
Anttila, Petra ;
Bloigu, Risto ;
Niemela, Onni .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2006, 83 (06) :1351-1354
[14]  
Shi Q, 2010, EXPERT REV GASTROENT, V4, P225, DOI [10.1586/egh.10.8, 10.1586/EGH.10.8]
[15]   Laboratory data in healthy volunteers: reference values, reference changes, screening and laboratory adverse event limits in phase I clinical trials [J].
Sibille, M ;
Deigat, N ;
Durieu, I ;
Guillaumont, M ;
Morel, D ;
Bienvenu, J ;
Massignon, D ;
Durand, DV .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (01) :13-19
[16]  
Southworth H, 2012, PHARM STAT, V11, P367, DOI 10.1002/pst.1531
[17]   Extreme value modelling of laboratory safety data from clinical studies [J].
Southworth, Harry ;
Heffernan, Janet E. .
PHARMACEUTICAL STATISTICS, 2012, 11 (05) :361-366
[18]   Detecting Outliers in Multivariate Laboratory Data [J].
Southworth, Harry .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2008, 18 (06) :1178-1183
[19]  
Trost Donald C, 2006, Toxicol Rev, V25, P37, DOI 10.2165/00139709-200625010-00003
[20]  
Tukey J. W., 1977, EXPLORATORY DATA ANA, V2